Qubigen to Present at WEHI Divisional Seminar Program on 20 Nov 2025
- David Brooks
- Nov 14, 2025
- 2 min read
Qubigen is pleased to announce that its CEO, Dr Jonathan Hall, and its Chief Information Officer, A/Prof Dr Jun Zeng, will be presenting at the Walter and Eliza Hall Institute of Medical Research (WEHI) Divisional Seminar Program. Hosted by Professor Guillaume Lessene, the seminar will explain how Qubigen’s proprietary Federated AI Platform (FedAIDD) is enabling a new paradigm in collaborative drug design.
Date | Thursday, 20 November 2025 |
Time | 10:45 to 11:45 AM |
Location | WEHI L7W Seminar Room | Bundoora Large Boardroom 1G Walter and Eliza Hall Institute/Royal Parade Parkville VIC 3050 Australia |
Online Access | |
Seminar Title | We Build AI Engines for Drug Design with our Secure Federated Platform |
Pioneering Secure Collaborative Drug Design
The drug development landscape faces increasing pressure to accelerate timelines, reduce costs and protect IP on increasingly complex projects, yet timelines remain long, risks are higher and costs are thinner than ever. By deploying a Federated AI architecture, Qubigen effectively addresses these barriers, allowing researchers to tap into high quality, diverse experimental data while preserving data security and maintaining privacy. Combined with proprietary molecular modelling and quantum chemistry virtual screening capabilities, Qubigen’s Federated AI for Drug Design (FedAIDD) platform accelerates the SAR process for more cost-effective and accurate identification of lead compounds, even for hard-to-drug or novel targets.
FedAIDD trains advanced AI Engines for drug design, utilizing data without transferring or accessing it directly. Built on a secure platform, it facilitates secure collaboration and delivers an end-to-end, application-specific workflow, producing actionable novel compounds for both classic and undruggable targets. The platform accelerates hit-to-lead optimization through secure analysis of molecular data, advanced virtual screening, GPU-parallelized quantum chemistry and the adaptable ability to select and curate the right data at arm's length, tailoring compounds to have specific physicochemical properties. Qubigen also has a validated, proprietary ADMET database to federate with client project data, that provides crucial chemical diversity and helps optimize compound properties.
Qubigen’s case studies highlight how its AI Engines can make 'cognitive leaps', designing highly novel compounds that match or outperform traditional methods even on limited and otherwise untrainable datasets. FedAIDD can also help to de-risk candidates by providing ADME-Tox analysis, improving selectivity, and assessing synthetic feasibility, to help reduce SAR and downstream costs.
Who Should Attend
This seminar is open to all, and is accessible via Teams, no registration required.
Don’t miss this unique opportunity to hear from Qubigen’s leadership about how FedAIDD is transforming the future of drug design pipelines. If you’re interested in exploring how Qubigen can support your own program, this seminar is a great place to start. We look forward to seeing you there.
Qubigen: accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure Federated AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
